MA31869B1 - Aminothiazoles et leurs utilisations - Google Patents

Aminothiazoles et leurs utilisations

Info

Publication number
MA31869B1
MA31869B1 MA32876A MA32876A MA31869B1 MA 31869 B1 MA31869 B1 MA 31869B1 MA 32876 A MA32876 A MA 32876A MA 32876 A MA32876 A MA 32876A MA 31869 B1 MA31869 B1 MA 31869B1
Authority
MA
Morocco
Prior art keywords
aminotiazole
atropisomers
rotamers
racemates
amelioration
Prior art date
Application number
MA32876A
Other languages
Arabic (ar)
English (en)
Inventor
Simon Bushell
Matthew J Lamarche
Jennifer Leeds
Lewis Whitehead
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40377437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31869(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31869B1 publication Critical patent/MA31869B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention porte sur des composés organiques qui sont utiles pour le traitement, la prévention de maladies et/ou l'amélioration de troubles pathologiques, en particulier d'infections bactériennes, formule (i), et sur des sels pharmaceutiquement acceptables de ces composés, des énantiomères, des stéréo-isomères, des rotamères, des tautomères, des diastéréomères, des atropisomères ou des racémates, notamment n-oxyde de pyridine.
MA32876A 2007-12-12 2010-05-31 Aminothiazoles et leurs utilisations MA31869B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1312207P 2007-12-12 2007-12-12
US2470908P 2008-01-30 2008-01-30
PCT/EP2008/067220 WO2009074605A1 (fr) 2007-12-12 2008-12-10 Aminothiazoles et leurs utilisations

Publications (1)

Publication Number Publication Date
MA31869B1 true MA31869B1 (fr) 2010-11-01

Family

ID=40377437

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32876A MA31869B1 (fr) 2007-12-12 2010-05-31 Aminothiazoles et leurs utilisations

Country Status (26)

Country Link
US (4) US8426356B2 (fr)
EP (1) EP2229386B1 (fr)
JP (2) JP5286366B2 (fr)
KR (2) KR101187111B1 (fr)
CN (1) CN101945866B (fr)
AR (1) AR069628A1 (fr)
AU (1) AU2008334659A1 (fr)
BR (1) BRPI0821138A2 (fr)
CA (1) CA2708793C (fr)
CL (1) CL2008003688A1 (fr)
CO (1) CO6290661A2 (fr)
CR (1) CR11469A (fr)
CU (1) CU20100119A7 (fr)
EA (2) EA201400280A1 (fr)
EC (1) ECSP10010244A (fr)
ES (1) ES2542878T3 (fr)
GT (1) GT201000166A (fr)
HN (1) HN2010001176A (fr)
IL (1) IL206104A (fr)
MA (1) MA31869B1 (fr)
MY (1) MY156466A (fr)
NZ (1) NZ585788A (fr)
PE (1) PE20091108A1 (fr)
TN (1) TN2010000254A1 (fr)
TW (1) TWI430804B (fr)
WO (1) WO2009074605A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080103A1 (es) * 2006-05-31 2008-04-03 Novartis Ag AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu
CA2708793C (fr) * 2007-12-12 2016-06-21 Novartis Ag Aminothiazoles et leurs utilisations
WO2016081825A1 (fr) * 2014-11-21 2016-05-26 KamTek, Inc. Procédés et compositions pour le traitement de maladie associée au clostridium difficile

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202241A (en) 1988-09-09 1993-04-13 Gruppo Lepetit S.P.A. Antibiotic GE 2270
ES2066914T3 (es) 1989-07-04 1995-03-16 Lepetit Spa Factores a1, a2, a3 y h del antibiotico ge 2270.
DK0451486T3 (da) 1990-03-08 1995-05-08 Lepetit Spa Antibiotikum GE 2270 faktorer B1, B2, C1, C2, D1, D2, E og T
IL100572A (en) 1991-01-03 1997-01-10 Lepetit Spa Amides of antibiotic ge 2270 factors their preparation and pharmaceutical compositions containing them
DE69224497T2 (de) 1991-08-30 1998-07-02 Biosearch Italia Spa Faktor C2a des Antibiotikums CE 2270
US5882900A (en) 1992-09-10 1999-03-16 Gruppo Lepetit S.P.A. Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
DE69317058T2 (de) 1992-12-22 1998-06-10 Biosearch Italia Spa Die antibiotika ge 37468 a, b und c
WO1996014427A1 (fr) 1994-11-08 1996-05-17 Gruppo Lepetit S.P.A. Procede de transformation microbienne permettant l'obtention du facteur d2 de l'antibiotique ge 2270
JP3518606B2 (ja) 1995-02-07 2004-04-12 バイオサーチ・イタリア・ソチエタ・ペル・アチオニ Ｇｅ２２７０及びｇｅ２２７０−様抗生物質の塩基性オキサゾリン−アミド誘導体
ATE165101T1 (de) 1995-02-07 1998-05-15 Biosearch Italia Spa Basische prolinamid derivate von ge2270 und ge2270-ahnlichten antibiotika
EP0880541B1 (fr) 1996-02-14 2003-01-15 Biosearch Italia S.p.A. Derives des facteurs de l'antibiotique ge2270
JPH1059997A (ja) 1996-08-22 1998-03-03 Microbial Chem Res Found アミチアマイシンアミド誘導体
DK1553967T3 (da) 2002-06-17 2011-08-29 Naicons S C A R L Anvendelse af et amidderivat af GE 2270 faktor A3 til behandling af acne
AU2005327139A1 (en) 2004-09-22 2006-08-17 Merck & Co., Inc. Antibiotic compound
WO2007007399A1 (fr) * 2005-07-13 2007-01-18 Taisho Pharmaceutical Co., Ltd. Dérivé de thiazole
PE20080103A1 (es) 2006-05-31 2008-04-03 Novartis Ag AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu
WO2008082562A2 (fr) 2006-12-20 2008-07-10 Novartis Ag Composés anti-bactériens et leurs procédés de fabrication
AU2008258639B2 (en) 2007-06-04 2012-07-05 Novartis Ag Macrocycles and their uses
CA2708793C (fr) * 2007-12-12 2016-06-21 Novartis Ag Aminothiazoles et leurs utilisations

Also Published As

Publication number Publication date
PE20091108A1 (es) 2009-08-24
EP2229386A1 (fr) 2010-09-22
US20090156628A1 (en) 2009-06-18
US8426356B2 (en) 2013-04-23
CO6290661A2 (es) 2011-06-20
IL206104A0 (en) 2010-11-30
TN2010000254A1 (en) 2011-11-11
ECSP10010244A (es) 2010-07-30
TW200932256A (en) 2009-08-01
CN101945866A (zh) 2011-01-12
AR069628A1 (es) 2010-02-03
ES2542878T3 (es) 2015-08-12
AU2008334659A1 (en) 2009-06-18
BRPI0821138A2 (pt) 2015-06-16
KR101187111B1 (ko) 2012-09-28
HN2010001176A (es) 2012-12-10
EP2229386B1 (fr) 2015-06-03
US9492496B2 (en) 2016-11-15
US20170015704A1 (en) 2017-01-19
EA201000890A1 (ru) 2011-02-28
US20140274878A1 (en) 2014-09-18
MY156466A (en) 2016-02-26
WO2009074605A1 (fr) 2009-06-18
KR20100090809A (ko) 2010-08-17
CN101945866B (zh) 2013-06-19
IL206104A (en) 2015-03-31
KR20120047335A (ko) 2012-05-11
JP2013189468A (ja) 2013-09-26
EA201400280A1 (ru) 2014-08-29
NZ585788A (en) 2011-07-29
US20130231275A1 (en) 2013-09-05
GT201000166A (es) 2012-04-30
CL2008003688A1 (es) 2009-06-19
TWI430804B (zh) 2014-03-21
CU20100119A7 (es) 2011-10-14
CA2708793A1 (fr) 2009-06-18
CR11469A (es) 2010-07-09
CU23908B1 (fr) 2013-06-28
EA020205B1 (ru) 2014-09-30
JP5286366B2 (ja) 2013-09-11
JP2011506394A (ja) 2011-03-03
CA2708793C (fr) 2016-06-21

Similar Documents

Publication Publication Date Title
MA31554B1 (fr) Indazoles à substitution amide utilises comme inhibiteurs de la poly(adp-ribose)polymérase (parp).
MA31419B1 (fr) Derives de pyridine
TNSN07022A1 (fr) Derives de pyridine
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
TW200508212A (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
NO20074959L (no) Substituerte pyridinderivater
MA31373B1 (fr) Composes amino-heterocycliques
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
MA42145A (fr) Triazoles agonistes du récepteur apj
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MX2009006195A (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
MX2012004848A (es) Compuestos heterociclicos triciclicos.
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
BR0116216A (pt) Inibidores de girase e seus usos
YU84603A (sh) Novi inhibitori tirozin kinaze
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
MA29926B1 (fr) Derives de pyrazine
UA92503C2 (ru) Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств
TN2009000028A1 (fr) Agonistes de ep2
MA33407B1 (fr) Composes bicycliques et tricycliques servant d'inhibiteurs de kat ii
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA30006B1 (fr) Composes anti-hypercholesterolemiques
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
MA29561B1 (fr) DERIVES DE PYRIDO[2,3-d] PYRIMIDINE, LEUR PREPARATION, LEUR APPLICATION EN THERAPEUTIQUE